Bristol-Myers Squibb Company (BMY)-BioNTech Lung Cancer Therapy Shows 76% Tumor Reduction

Group 1: Company Overview - Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical leader specializing in oncology, immunology, cardiovascular, hematology, and neuroscience therapies, with notable drugs such as Eliquis and Opdivo [1] - The company has launched a new independent biotech focused on autoimmune disease therapies, funded with $300 million, retaining a 20% stake [2] Group 2: Recent Developments - BMY is advancing immunotherapy for lung cancer, with a Phase II trial showing a 76% tumor reduction rate for BNT327/pumitamig, now in Phase III trials supported by a collaboration valued at up to $11.1 billion [3] - A clinical trial for Iza-bren, an investigational breast cancer therapy, was launched in July 2025, targeting patients unsuitable for conventional immunotherapies [4] Group 3: Financial Performance - In Q2 2025, Eliquis sales rose 8% to $3.7 billion, while Opdivo revenue grew 7% to $2.6 billion, indicating strong revenue from established products alongside an expanding pipeline [5]